Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2019-04-25 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
2019年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2019年第一季度报告正文" which translates to "2019 First Quarter Report Main Text." It contains detailed financial data for the quarter, including revenue, net profit, cash flow, earnings per share, and other financial indicators. It also includes shareholder information and explanations of financial changes during the quarter. The length of the document (over 10,000 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive quarterly financial report. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2019
2019-04-25 Chinese
关于举行2018年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the holding of the 2018 annual performance explanation meeting (业绩说明会), specifying the date, time, and platform for the event. It mentions key company executives who will attend and invites investors to participate. The document does not contain actual financial data or detailed financial results but rather serves as a notice for an upcoming event where such information might be discussed. The document length is short (488 characters), and it is clearly an announcement rather than a report or transcript. Therefore, it fits best into the category of Investor Presentation (IP) or possibly Call Transcript (CT) if it were the transcript itself. However, since this is an announcement of the event, not the transcript, and the closest category for such an announcement of a performance explanation meeting is Investor Presentation (IP).
2019-04-07 Chinese
关于召开2018年度股东大会通知的更正公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2018 Annual General Meeting (AGM) of 华兰生物工程股份有限公司. It includes corrections to previous notices, detailed agenda items for the AGM, voting procedures including network voting instructions, proxy forms, and information about the election of board members and supervisors. The content focuses on the organization and conduct of the AGM, including voting details and procedural instructions, rather than presenting financial results or management analysis. There is no indication that this is the actual annual report or financial statements, nor is it a transcript or earnings release. The document is clearly a notice and procedural guide for the AGM, which fits the category of AGM Information (AGM-R). The document length and detail confirm it is not a brief announcement but a full AGM notice with attachments and instructions.
2019-04-01 Chinese
关于部分高管减持计划时间过半未减持公司股份的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the progress of a shareholding reduction plan by a company executive. It details that the executive has not yet reduced shares as planned and confirms compliance with relevant laws and regulations. The document is short (1320 characters) and focuses on insider share transactions by a company director. It does not contain financial statements or performance data, nor is it a report or presentation. Therefore, it fits the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives.
2019-04-01 Chinese
独立董事2018年度述职报告（田莉军）
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of a company for the year 2018. It includes descriptions of attendance at board meetings, independent opinions on related party transactions, internal control evaluation, audit firm appointment, investment and financing matters, profit distribution proposals, guarantees, stock incentive plans, and other governance-related activities. The content is focused on the independent director's duties and opinions regarding the company's governance and compliance during the year. It is not a full annual report or financial statement, nor is it a brief announcement or a transcript. It is a specific report by an independent director on their annual duties and opinions, which fits the category of Board/Management Information (MANG) as it relates to management and board-level disclosures about governance and oversight activities.
2019-03-28 Chinese
独立董事候选人声明（章金刚）
Regulatory Filings Classification · 95% confidence The document is a detailed declaration by an independent director candidate of a company, confirming compliance with various legal and regulatory requirements for serving as an independent director. It includes statements about qualifications, independence, and adherence to relevant laws and regulations. There is no financial data, no mention of financial results, no report or announcement of voting results, no management changes, and no other financial or corporate event disclosures. This type of document is a regulatory compliance filing related to corporate governance but does not fit into categories like Annual Report, Management Information, or Proxy Solicitation. It is a formal declaration submitted to the stock exchange and regulatory bodies, thus best classified under Regulatory Filings (RNS). The document length is under 5,000 characters and is a standalone declaration, not an announcement of a report publication or a report itself.
2019-03-28 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.